Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?

Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Psychoneuroendocrinology (Impact Factor: 4.94). 08/2008; 33(6):711-7. DOI: 10.1016/j.psyneuen.2008.02.008
Source: PubMed


To assess the degree to which sexual side effects (SSE) are associated with prolactin-raising antipsychotics, and to what degree such SSE are reducible to serum prolactin levels.
A large sample (n=264) of patients treated for 6 weeks with prolactin-raising and prolactin-sparing antipsychotics was assessed for changes in sexual performance in terms of libido, arousal and orgasm using the Antipsychotics and Sexual Functioning Questionnaire. For men also erection and ejaculation were evaluated. At 6 weeks, prolactin levels were assessed and analyzed in relation to sexual performance.
Men and women reported SSE (libido and orgasm) with about the same frequency. Prolactin-raising medication induced significantly more SSE than prolactin-sparing medication (adjusted OR=3.4, 95% CI: 1.8, 6.5) with 43% of emerging SSE attributable to prolactin-raising medication. When adjusted for serum prolactin, the association between prolactin-raising medication and SSE was reduced but remained significant (OR=2.1, 95% CI: 1.0, 4.5); 27% of emerging SSE remained attributable to prolactin-raising medication. For erectile and ejaculatory dysfunction in men, the attributable fraction due to prolactin-raising medication was 32% before, and 11% after adjustment for serum prolactin.
Around 40% of emerging SSE in schizophrenia are attributable to the prolactin-raising properties of antipsychotic medication. Of this attributable fraction, around one-third to two-thirds is directly reducible to the effects of serum prolactin.

Download full-text


Available from: Richard Bruggeman, Apr 01, 2015
  • Source
    • "Psychopharmacological medications have also been shown to negatively affect erectile functioning. One study found impaired sexual arousal and desire in 14% of patients taking lithium (Aizenberg, Sigler, Zemishlany, & Weizman, 1996), and antipsychotic medications have also been shown to affect sexual functioning (Dossenbach et al., 2005; Knegertin et al., 2008; Meston & Frohlich, 2000). Antidepressants have shown the most consistent association with sexual problems, including erectile functioning. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Journal of Sexual Aggression: An international, interdisciplinary forum for research, theory and practice Publication details, including instructions for authors and subscription information: makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses,
    Journal of Sexual Aggression 04/2014; 21(3). DOI:10.1080/13552600.2014.900121
  • Source
    • "Sexual dysfunction is rarely reported spontaneously , leading to underestimation of its prevalence. In contrast, studies using structured interviews or questionnaires show that 16 to 60% of the patients experience sexual dysfunction (Knegtering et al., 2008; Serretti and Chiesa, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to describe the psychometric properties of the Antipsychotics and Sexual Functioning Questionnaire (ASFQ). Internal reliability, test-retest reliability, inter-rater reliability, validity and sensitivity to change were calculated in a sample of 30 patients with schizophrenia or a schizophrenia spectrum disorder using antipsychotics. The ASFQ is a semistructured interview, with good face validity and content validity, that takes on average about 10min to complete. The ASFQ has good internal reliability (Cronbach's alpha 0.84) and good test-retest reliability (mean Spearman's rho=.76). The inter-rater reliability is good for questions about libido, orgasm, erection and ejaculation. Correlation coefficients for calculating convergent validity were modest to good when comparing the ASFQ with the corresponding items on the Subject's Response to Antipsychotics (SRA) questionnaire and the Arizona Sexual Experience Scale (ASEX). Based on preliminary evidence, it can be concluded that the Antipsychotics and Sexual Functioning Questionnaire has reasonable reliability and is available for clinical use and research.
    Schizophrenia Research 09/2013; 150(2-3). DOI:10.1016/j.schres.2013.08.037 · 3.92 Impact Factor
  • Source
    • "Sexual dysfunction associated with antipsychotics is a common problem in patients with schizophrenia, especially in men (Knegtering et al., 2008; Montejo et al., 2010a). The prevalence of sexual dysfunction in patients treated with conventional antipsychotics is 40–60% in men (Cutler, 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotic-induced sexual dysfunction is a common problem in patients with schizophrenia. The aim of the study was to investigate the effect of switching to aripiprazole on sexual dysfunction and the hypothalamic-pituitary-gonadal axis in male patients with schizophrenia. In this prospective, open-label study, the participants were 10 male schizophrenia patients treated with atypical antipsychotics, risperidone, amisulpride, and olanzapine. Before and after switching to aripiprazole, they were assessed on the Arizona Sexual Experience Scale, and hormonal levels were measured. Our results showed a significant improvement in the severity of sexual dysfunction, especially in 'ease of sexual arousal' and 'penile erection,' as measured by the Arizona Sexual Experience Scale total scores after switching to aripiprazole (χ(2) = 12.45 and P = 0.002). The serum prolactin level decreased significantly after switching to aripiprazole (χ(2) = 11.14 and P = 0.004), but the changes in the total testosterone level were not significant (χ(2) = 4.75 and P = 0.93). Our results suggest that sexual dysfunction in schizophrenia patients seems to improve after switching to aripiprazole from other atypical antipsychotics (risperiodone, amisulpride, or olanzapine). This may be associated with a change in dopamine and serotonin transmissions and a decrease in the serum prolactin concentration.
    International clinical psychopharmacology 03/2012; 27(4):177-83. DOI:10.1097/YIC.0b013e328351c8c4 · 2.46 Impact Factor
Show more